The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Open accessAbstract
BACKGROUND: Apolipoprotein C-III (APOC3) is a key regulator of plasma triglyceride levels. Elevated triglyceride levels are associated with a risk of adverse cardiovascular events and pancreatitis. ISIS 304801 is a second-generation antisense inhibitor of APOC3 synthesis. METHODS: We conducted a randomized, double-blind, placebo-controlled, dose-ranging, phase 2 study to evaluate ISIS 304801 in untreated patients with fasting triglyceride levels between 350 mg per deciliter (4.0 mmol per liter) and 2000 mg per deciliter (22.6 mmol per liter) (ISIS 304801 monotherapy cohort), as well as in patients receiving stable fibrate therapy who had fasting triglyceride levels between 225 mg per deciliter (2.5 mmol per liter) and 2000 mg per deciliter (ISIS 304801-fibrate cohort). Eligible patients were randomly assigned to receive either ISIS 304801, at doses ranging from 100 to 300 mg, or placebo, once weekly for 13 weeks. The primary outcome was the percentage change in APOC3 level from baseline. RESULTS: A total of 57 patients were treated in the ISIS 304801 monotherapy cohort (41 received active agent, and 16 received placebo), and 28 patients were treated in the ISIS 304801-fibrate cohort (20 received active agent, and 8 received placebo). The mean (±SD) baseline triglyceride levels in the two cohorts were 581±291 mg per deciliter (6.6±3.3 mmol per liter) and 376±188 mg per deciliter (4.2±2.1 mmol per liter), respectively. Treatment with ISIS 304801 resulted in dose-dependent and prolonged decreases in plasma APOC3 levels when the drug was administered as a single agent (decreases of 40.0±32.0% in the 100-mg group, 63.8±22.3% in the 200-mg group, and 79.6±9.3% in the 300-mg group, vs. an increase of 4.2±41.7% in the placebo group) and when it was administered as an add-on to fibrates (decreases of 60.2±12.5% in the 200-mg group and 70.9±13.0% in the 300-mg group, vs. a decrease of 2.2±25.2% in the placebo group). Concordant reductions of 31.3 to 70.9% were observed in triglyceride levels. No safety concerns were identified in this short-term study. CONCLUSIONS: We found that treatment with ISIS 304801 was associated with significant lowering of triglyceride levels, among patients with a broad range of baseline levels, through selective antisense inhibition of APOC3 synthesis. (Funded by Isis Pharmaceuticals; ClinicalTrials.gov number, NCT01529424.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a randomized, placebo-controlled, double-blind phase 2 trial of 57 patients with elevated triglycerides, volanesorsen reduced ApoC-III by up to − 80% and triglycerides by − 71% [175].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [175]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Volanesorsen is an antisense oligonucleotide that targets APOC3 messenger RNA (mRNA) and reduces plasma apolipoprotein C-III levels, as well as the degree of chylomicronemia and plasma triglyceride levels.”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Volanesorsen (previously known as ISIS-APOC-III RX ) is a second-generation ASO developed to inhibit apoCIII”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [170]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Volanesorsen, a second-generation antisense oligonucleotide (ASO) targeting hepatic APOC3 mRNA, has shown the capacity to lower TG by up to 77% in patients with Familial chylomicronemia syndrome (FCS) [114]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [114]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several miRNAs and antisense oligonucleotides (ASOs) are currently under investigation in clinical trials for various diseases (Kanasty et al., 2013;van Rooij and Kauppinen, 2014;Gaudet et al., 2015).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Gaudet et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Several novel therapies that potently reduce triglyceride levels are currently in development.[6][7][8]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [8]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The agent has been approved in the European Union and the United Kingdom for the treatment of familial chylomicronemia syndrome and in Brazil for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. 23-25”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [24]
Experimental — accuracy not yet measuredIn the citing paper
“In a Phase 2 trial of volanesorsen, 300 mg given weekly to HTG patients (NCT01529424), TG levels were reduced by 80%.68”
From Clinical review on triglycerides (2020) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Flagged first, then by citations
1 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Brunzell JD, 1973, Trans Assoc Am Physicians, 86, 245
Cited by
Sorted by citations
Items 401–500 of 530
Therapeutic oligonucleotides in cardiovascular and metabolic diseases: insights for the internist
Girelli, D., Busti, F., Marchi, G., Martinelli, N., & Olivieri, O. (2018) · Internal and Emergency Medicine · doi:10.1007/s11739-018-1810-5 · Cited by 5
Beyond Statins: Who and When to Prescribe?
Ganda, O. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1087-0 · Cited by 5
Palmisano, B. T., Zhu, L., Litts, B., Burman, A., Yu, S., Neuman, J. C., Anozie, U., Luu, T. N., Edington, E. M., & Stafford, J. M. (2021) · Metabolites · doi:10.3390/metabo11050330 · Cited by 7
Deep Apolipoprotein Proteomics to Uncover Mechanisms of Coronary Disease Risk ∗
Rader, D. J., Bajaj, A., & Khetarpal, S. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.066 · Cited by 5
Do Elevated Triglycerides Truly Trigger Acute Pancreatitis?
Faghih, M., & Singh, V. K. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05501-0 · Cited by 5
Lipoprotein Metabolism and Cholesterol Balance
Acuña, M., & Cohen, D. E. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch22 · Cited by 5
Erbasan, E., Aliciaslan, M., Erendor, F., Şanlioğlu, A. D., & Şanlıoğlu, S. (2025) · Gene Therapy · doi:10.1038/s41434-025-00575-0 · Cited by 5
Qiu, Z., Wang, R.-Y., Zhang, Y., Huang, H.-B., He, R.-Y., Yan, H., Luo, P., Yang, B., Xu, Z.-F., & He, Q.-J. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01729-x · Cited by 6
Usova, E., Alieva, A. S., Yakovlev, A. N., Makarova, T. A., Алиева, М. С., Конради, А. О., Catapano, A. L., & Shlyakhto, E. V. (2022) · Russian Journal for Personalized Medicine · doi:10.18705/2782-3806-2022-2-2-6-16 · Cited by 4
Simultaneous Quantification of Apolipoprotein C-III O-Glycoforms by Protein-MRM
Kim, H., Cheon, D. H., Yang, W. S., & Baek, J. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00490 · Cited by 4
Larouche, M., Brisson, D., Morissette, M.-C., & Gaudet, D. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02743-0 · Cited by 4
Self-citationHepatic Abnormal Secretion of Apolipoprotein C3 Promotes Inflammation in Aortic Dissection
Zhuang, X., Zarif, M., Shen, Y., Zhang, Z., He, J., Xie, L., Wu, Q., Lin, X., Chen, K., Tian, Y., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037172 · Cited by 4
Fu, L., Liu, Q., Cheng, H., Zhao, X., Xiong, J., & Mi, J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038857 · Cited by 4
Pan, J. B., Wang, X., Zhang, Y., Wang, T., Lv, S., Zhang, X., Zhou, Y., Peng, T., & Song, Y. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70542 · Cited by 4
Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Bharadiya, V. M., Rawal, S., Jain, V., Chevli, P. A., & Mehta, A. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00702-1 · Cited by 5
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
Lipoprotein and Lipid Metabolism
Hegele, R. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-812535-9.00007-8 · Cited by 6
New and Emerging Therapies for Dyslipidemia
Zambon, A., Averna, M. R., D’Erasmo, L., Arca, M., & Catapano, A. L. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.004 · Cited by 4
Investigational therapies for hypercholesterolemia
TOMKIN, G. H., & Owens, D. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1315407 · Cited by 4
Antisense Oligonucleotides for the Treatment of Hypertriglyceridemia and Hyperlipoproteinemia(a)
Hanßen, R., & Gouni‐Berthold, I. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0115-0 · Cited by 4
Davidson, J., & Rotondo, D. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000510 · Cited by 4
Walking the VLDL tightrope in cardiometabolic diseases
Kim, M., & Zheng, Z. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.020 · Cited by 4
Nguyen, T. N., Kim, H.-J., Shim, H. M., Kang, J., Ha, E. Y., Cho, H., & Park, J. (2026) · Biomolecules · doi:10.3390/biom16040607 · Cited by 3
A very rare case of chylomicronemia revealed by cerebral thrombophlebitis in a 4-month-old infant
Es-Saad, O., Lamzouri, O., Bouchlarhem, A., Haddar, L., Aabdi, M., Mimouni, H., zerouati, K., Bkiyar, H., & Housni, B. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.103276 · Cited by 3
Current drugs, targets, and drug delivery systems for the treatment of dyslipidemia
Yang, S., & Moon, Y.-A. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0353-5 · Cited by 3
Elevated triglycerides: A matter of the heart and pancreas
Blom, D. J. (2018) · South African Medical Journal · doi:10.7196/samj.2018.v108i4.13235 · Cited by 3
Shou, W., Zhang, C., Shi, J., Wu, H., & Huang, W. (2020) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.11.010 · Cited by 3
FISIOPATOLOGIA E TRATAMENTOS ATUALMENTE DISPONÍVEIS PARA DISLIPIDEMIA
Almeida, A. B., Pontes, B. B., Gioia, L. N., & Rangel, V. (2023) · EPITAYA eBooks · doi:10.47879/ed.ep.2023809p32 · Cited by 3
Translational bioinformatics approach to combat cardiovascular disease and cancers
Shahjahan, Dey, J. K., & Dey, S. K. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.11.006 · Cited by 3
New Biotechnological Treatments for Lipid Disorders
Valencia‐Enciso, N., & Mendivil, C. O. (2018) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.18002577 · Cited by 3
Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro
Iwashita, S., Shoji, T., & Koizumi, M. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0771-8_11 · Cited by 3
Recruiting a transcription factor in the liver to prevent atherosclerosis
Attie, A. D. (2021) · Journal of Clinical Investigation · doi:10.1172/jci154677 · Cited by 3
Conroy, R., Mackie, S. A., & Boney, C. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-73782-9_33 · Cited by 3
Rader, D. J., & Kathiresan, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801812-5.00001-9 · Cited by 3
Nonstatin Therapy for Dyslipidemia
Ahmed, H. M., & Nissen, S. E. (2018) · Circulation Research · doi:10.1161/circresaha.118.313829 · Cited by 3
Besci, Ö., Güler, M. Ç., Foss‐Freitas, M. C., & Oral, E. A. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2574318 · Cited by 2
Bajaj, A., Oral, E. A., Brown, A. S., Gaudet, D., Alexander, V. J., Karwatowska‐Prokopczuk, E., & Baum, S. J. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101352 · Cited by 2
Self-citationPechetty, R., Rao, P. S., Deb, T., Shekar, C., & Deepthi, K. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_55_2025 · Cited by 2
Antisenses working overtime in lipids
Farhan, S. M. K., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.146 · Cited by 2
Inhibiting apoC-III synthesis in patients with hypertriglyceridaemia
Huynh, K. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.127 · Cited by 2
The year in cardiology 2015: prevention.
Chapman, M. J., Blankenberg, S., & Landmesser, U. (2016) · Cardiologia Croatica · doi:10.15836/ccar2016.218 · Cited by 2
Advances in the management of dyslipidemia
Kampangkaew, J., Pickett, S., & Nambi, V. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000415 · Cited by 2
Association of Apolipoprotein C3 Levels and Hepatic Steatosis: A Follow-Up Study
Heinz, P., Boehm, B. O., Schmidberger, J., Kratzer, W., & for the EMIL-Study Group (2020) · Hormone and Metabolic Research · doi:10.1055/a-1116-2333 · Cited by 2
Insulin can be used to treat severe hypertriglyceridaemia in pregnant women without diabetes
Ali, A. S. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-243508 · Cited by 2
Gaudet, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00035-2 · Cited by 2
Self-citationConroy, R., Mackie, S. A., & Boney, C. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_32 · Cited by 2
Hypertriglyceridaemia: Contemporary management of a neglected cardiovascular risk factor
Khan, T. Z., Schatz, U., Bornstein, S. R., & Barbir, M. (2021) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2021.19 · Cited by 2
Slippery Slope of Triglycerides
Watson, K. E., & Wiesner, P. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.002675 · Cited by 2
Lipid metabolism: spotlight on modulators of lipoprotein lipase activity
Arndt, L., & Burkhardt, R. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000501 · Cited by 2
Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00125-0 · Cited by 2
Luo, F., Yu, L., Xian, X., Shan, B., & Das, A. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1364170 · Cited by 2
Elbahloul, M. A., Gamal, A., Maihoub, O., Elbaz Hassan, M. M., Attia, M. K., Salah, A. M., Elboraay, T., Awad, A. K., Akoum, A., Elazab, A., et al. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70717 · Cited by 1
Clinical Management of Dyslipidemia in Infants and Toddlers
Kelley, J. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01305-y · Cited by 1
Meta-analysis of adverse events in clinical studies with antisense oligonucleotide therapies
Vermeer, C., Venema, R. R., Birnie, E., Bolling, M. C., Knoers, N. V. A. M., Bremer, J., & van den Akker, P. C. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102976 · Cited by 1
Efficacy and safety of olezarsen in patients with vs without baseline fibrate use
Wang, A. Z., Alexander, V. J., Prohaska, T. A., Ran, X., Goodrich, E. L., Murphy, S. A., Zimerman, A., Moura, F. A., Kang, Y. M., Nordestgaard, B. G., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.08.001 · Cited by 1
Self-citationThe 10thAnnual Cardiometabolic Health Congress General Session Highlights
Cerrato, P. L., & Mihalovic, M. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1175236 · Cited by 1
Investigated treatments for lipoprotein lipase deficiency and related metabolic disorders
Lee, J.-H., & Hegele, R. A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1311784 · Cited by 1
Hypertriglyzeridämie und HDL-Mangel
von Eckardstein, A. (2017) · Praxis · doi:10.1024/1661-8157/a002760 · Cited by 1
Gamad, N., Shafiq, N., & Malhotra, S. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136569 · Cited by 1
Translating Evidence From Clinical Trials of omega-3 Fatty Acids to Clinical Practice
Nelson, A. J., & Nicholls, S. J. (2020) · Future Cardiology · doi:10.2217/fca-2019-0031 · Cited by 1
Hypertriglycéridémies, démarche clinique et thérapeutique
Lecerf, J. (2020) · Pratiques en nutrition · doi:10.1016/j.pranut.2020.06.010 · Cited by 1
Genetic Disorders of Lipoprotein Metabolism
Brown, A. S., Dababneh, E. G., Chaus, A. M., Chyzhyk, V., Marinescu, V., & Pyslar, N. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_3 · Cited by 1
Hohes Pankreatitisrisiko bei familiärem Chylomikronämie-Syndrom
Klose, G. (2021) · Gastro-News · doi:10.1007/s15036-021-2424-8 · Cited by 1
Etitiological Relationship between Hyperlipidemia and Acute Pancreatitis
Li, H., Li, J., Tan, X., & Zhang, Q. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.125005 · Cited by 1
Advances in Hypercholesterolemia
Pirillo, A., Norata, G. D., & Catapano, A. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12435-7 · Cited by 1
Therapies Targeting HDLc Levels and HDL Function
Vitali, C., & Cuchel, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812513-7.00012-4 · Cited by 1
Titov, V. N., Ta, R., Ивановна, К. В., & Alchinova, I. B. (2019) · Russian Clinical Laboratory Diagnostics · doi:10.18821/0869-2084-2019-64-1-4-13 · Cited by 1
Síndrome de Quilomicronemia Familiar: Algoritmo Diagnóstico
Colaco, I. B., Araújo, F., Aguiar, P., Cruz, D., Bourbon, M., Duarte, J. S., & Veríssimo, M. T. (2021) · Medicina Interna · doi:10.24950/rspmi.r.92.4.2021 · Cited by 1
Apolipoprotein Gene Structure and Function
Martín-Campos, J. M., Chang, B. H.-J., Blanco‐Vaca, F., Chan, L., & Julve, J. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0005909.pub3 · Cited by 1
Lotta, L. A., Dong, L., Li, C., Patel, S., Stewart, I. D., Lim, K., Day, F. R., Wheeler, E., Glastonbury, C. A., de Streek, M. V., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/372128 · Cited by 2
Vitali, C., Stankov, S. G., Khetarpal, S. A., Millar, J. S., Mayne, L. C., Englander, S. W., Hand, N. J., Lund‐Katz, S., Phillips, M. C., & Rader, D. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.02.183178 · Cited by 1
Targeting triglycerides for cardiovascular risk reduction
Maiorca, C., Tramontano, D., Di Costanzo, A., & D’Erasmo, L. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04383-1
Korb, A., Sonnekus, P. H., & Botha, J. (2015) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2015.1118230
Antisense Oligonucleotides for Treatment of Dyslipidemia
Watson, K. E., & Facc (2015) · Journal watch · doi:10.1056/nejm-jw.na38567
Emerging molecular strategies for management of dyslipidemias
Kane, J. P., & Malloy, M. J. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000243
Parhofer, K. G. (2016) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-016-7653-y
Godina 2015. u kardiologiji: prevencija The year in cardiology 2015: prevention
Chapman, M. J., Blankenberg, S., & Landmesser, U. (2016)
Fettstoffwechsel: Diagnostik, Bewertung und Behandlung primärer Dyslipoproteinämien
März, W., & Klose, G. (2017) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/s-0037-1618961
Hypertriglyzeridämie und HDL-Mangel
von Eckardstein, A. (2017) · CardioVasc · doi:10.1007/s15027-017-1275-x
4. Management of Disorders of Lipoprotein Metabolism-Update-
Ishibashi, S. (2018) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.107.453
Domenecha, M., Estruch, R., Moreno, R., & Sánchez, M. A. (2017) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(19)30012-3
Regulation of Lipoprotein Lipase Activity : an In-vitro Study of a Complex and Dynamic System
Kovrov, O. (2019) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?
Nelson, A. J., Mirzaee, S., & Nicholls, S. J. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00363-3
Constructing roadmaps towards functional cell types using organoids
Beumer, J. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/125
Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis
Ward, N. C., & Watts, G. F. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_33
Björnson, E. (2021) · Gothenburg University Publications Electronic Archive (Gothenburg University)
New Agents for Treatment of Dyslipidemia
Simha, V. (2021) · Clinical Dilemmas in Diabetes · doi:10.1002/9781119603207.ch17
Innovative Lipid Biomarkers and Long-Term Outcomes
Anderson, J. L. C. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.192996734
Rye, K., & Barter, P. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_6075
Quispe, R., Das, T. M., & Michos, E. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-75055-8_2
Rye, K., & Barter, P. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-21573-6_6075-1
Hussain, A., & Ballantyne, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00028-5
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Bobik, A., Cohen, N. D., Jenkins, A. J., Kyaw, T. S., SULLIVAN, D. R., Wu, X., Yu, X.-Y., & Little, P. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_30
CARDIOLOGIA EM FOCO: PREVENÇÃO, DIAGNÓSTICO E TRATAMENTOS ATUAIS
Almeida, A. B., & Horevicht, C. M. (2023) · EPITAYA eBooks · doi:10.47879/ed.ep.2023809
Gilyarevskiy, S. R. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-268
RNA interference-based therapies for atherosclerosis: Recent advances and future prospects
Parsamanesh, N., Poudineh, M., Siami, H., Butler, A. E., Almahmeed, W. A., & Sahebkar, A. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.009 · Cited by 1
Li, J., Sun, H., Wang, Y., Liu, J., & Wang, G. (2023) · Figshare · doi:10.6084/m9.figshare.22613807
Li, J., Sun, H., Wang, Y., Liu, J., & Wang, G. (2023) · Figshare · doi:10.6084/m9.figshare.22613810
Li, X., Huang, Z., Tian, Y., Chen, X., Wu, H., & Wang, T. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2024.1305570
Metadata
- Authors
- Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., Crooke, R. M., Witztum, J. L., Brunzell, J. D., & Kastelein, J. J. P.
- Affiliations
- University of Washington (US)
- Ionis Pharmaceuticals (United States) (US)
- Université de Montréal (CA)
- University of California San Diego (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-30
- Volume
- 373
- Issue
- 5
- Pages
- 438-447
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2315899065
- Semantic Scholar
- b8b4f0ae969760d3373ca1d9082abfee85fe16d9
- Cited by
- 528
- References
- 51
- Citations by year
- 2026: 23 · 2025: 28 · 2024: 27 · 2023: 32 · 2022: 51 · 2021: 46 · 2020: 63 · 2019: 61 · 2018: 68 · 2017: 58 · 2016: 58 · 2015: 13
- FWCI
- 47.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, antisense oligonucleotides, hypertriglyceridemia, triglyceride lowering, fibrate therapy, dose-ranging, cardiovascular risk, pancreatitis risk, triglyceride metabolism, monotherapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Cholesterol, HDL, Male, Middle Aged, Oligonucleotides, Triglycerides, Hypertriglyceridemia, Apolipoprotein C-III, Fibric Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
